|
Name |
Okanin 4'-(6''-acetylglucoside)
|
Molecular Formula | C23H24O12 | |
IUPAC Name* |
[(3S,4S,6S)-6-[4-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-2,3-dihydroxyphenoxy]-3,4,5-trihydroxyoxan-2-yl]methyl acetate
|
|
SMILES |
CC(=O)OCC1[C@H]([C@@H](C([C@@H](O1)OC2=C(C(=C(C=C2)C(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O)O)O)O
|
|
InChI |
InChI=1S/C23H24O12/c1-10(24)33-9-17-20(30)21(31)22(32)23(35-17)34-16-7-4-12(18(28)19(16)29)13(25)5-2-11-3-6-14(26)15(27)8-11/h2-8,17,20-23,26-32H,9H2,1H3/b5-2+/t17?,20-,21+,22?,23-/m1/s1
|
|
InChIKey |
PLCKXYSWZCDSJH-DZAQGCCUSA-N
|
|
Synonyms |
Okanin 4'-(6''-acetylglucoside); LMPK12120157
|
|
CAS | NA | |
PubChem CID | 42607561 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 492.4 | ALogp: | 0.7 |
HBD: | 7 | HBA: | 12 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 203.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 35 | QED Weighted: | 0.123 |
Caco-2 Permeability: | -6.305 | MDCK Permeability: | 0.00000990 |
Pgp-inhibitor: | 0.012 | Pgp-substrate: | 0.075 |
Human Intestinal Absorption (HIA): | 0.358 | 20% Bioavailability (F20%): | 0.018 |
30% Bioavailability (F30%): | 0.993 |
Blood-Brain-Barrier Penetration (BBB): | 0.055 | Plasma Protein Binding (PPB): | 97.03% |
Volume Distribution (VD): | 0.414 | Fu: | 5.33% |
CYP1A2-inhibitor: | 0.099 | CYP1A2-substrate: | 0.031 |
CYP2C19-inhibitor: | 0.029 | CYP2C19-substrate: | 0.052 |
CYP2C9-inhibitor: | 0.031 | CYP2C9-substrate: | 0.141 |
CYP2D6-inhibitor: | 0.1 | CYP2D6-substrate: | 0.181 |
CYP3A4-inhibitor: | 0.073 | CYP3A4-substrate: | 0.042 |
Clearance (CL): | 4.586 | Half-life (T1/2): | 0.935 |
hERG Blockers: | 0.213 | Human Hepatotoxicity (H-HT): | 0.134 |
Drug-inuced Liver Injury (DILI): | 0.796 | AMES Toxicity: | 0.82 |
Rat Oral Acute Toxicity: | 0.214 | Maximum Recommended Daily Dose: | 0.016 |
Skin Sensitization: | 0.941 | Carcinogencity: | 0.6 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.629 |
Respiratory Toxicity: | 0.036 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004734 | 0.434 | D0KN2M | 0.390 | ||||
ENC001572 | 0.417 | D0I9HF | 0.357 | ||||
ENC001848 | 0.404 | D06BQU | 0.339 | ||||
ENC005772 | 0.398 | D0TC7C | 0.321 | ||||
ENC002269 | 0.396 | D0V9EN | 0.313 | ||||
ENC001579 | 0.395 | D0Q0PR | 0.297 | ||||
ENC002201 | 0.394 | D0Z2LG | 0.293 | ||||
ENC001546 | 0.386 | D09LBS | 0.293 | ||||
ENC005169 | 0.383 | D0E6OC | 0.286 | ||||
ENC004475 | 0.382 | D01TNW | 0.281 |